New STING agonist drug enters human trials for Hard-to-Treat cancers

NCT ID NCT06021626

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. The goal is to find the safest dose and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CRD3874-SI (a STING agonist drug given by IV infusion)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors like sarcoma and Merkel cell carcinoma.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if the drug will work. Side effects are unknown, and the drug may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACRAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acral lentiginous melanoma adenoid cystic carcinoma cutaneous neuroendocrine carcinoma head and neck squamous cell carcinoma mucosal melanoma non-small cell lung carcinoma sarcoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MERKEL CELL CARCINOMA SARCOMA

Contacts and locations

Locations

Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITING

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.